GlassScriptPhysician profile
Evan Reinhardt
NPI 1518306836
$847.47
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $135.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $128.13 | 2019 | |
| Amgen INC. | $102.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.58 | 2019 | |
| Novo Nordisk INC | $65.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.73 | 2019 | |
| Gilead Sciences, INC. | $37.05 | 2019 | |
| Pfizer INC. | $34.56 | 2019 | |
| Astellas Pharma US INC | $27.58 | 2019 | |
| Lilly USA, LLC | $27.12 | 2019 | |
| Amarin Pharma, INC. | $21.32 | 2019 | |
| Cranial Technologies, INC | $18.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.18 | 2019 | |
| Shire North American Group INC | $15.65 | 2019 | |
| Antares Pharma, INC. | $14.92 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $13.69 | 2019 | |
| Glaxosmithkline, LLC. | $13.41 | 2019 | |
| Dynavax Technologies Corporation | $13.25 | 2019 | |
| Circassia INC. | $12.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.05 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Reinhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.